(Press-News.org) Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows.
The research, published in the October issue of the journal Clinical Cancer Research, provides important evidence that PARP inhibitor drugs and chemotherapy can both be effective in the same patients, helping women live longer than they would if treated with chemotherapy alone.
The study, in women with mutations to BRCA genes – which increase the risk that ovarian cancer will relapse after treatment, as well as being linked to breast and other cancers – showed that ovarian cancers that have become resistant to PARP inhibitors often remain sensitive to conventional chemotherapy.
The study was led by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and looked at follow-up data from patients who had previously taken part in clinical trials sponsored by pharmaceutical company AstraZeneca. The research was supported by grants from the Experimental Cancer Medicine Centre and a range of institutions including Cancer Research UK, the National Institute for Health Research and the Wellcome Trust.
The researchers monitored 89 patients with BRCA-mutated ovarian cancer at The Royal Marsden and other hospitals in the UK, Australia, Belgium, Israel and North America, all of whom received chemotherapy following the development of resistance to a PARP inhibitor called olaparib.
Almost half (49 per cent) of olaparib-resistant patients showed a significant decrease in the size of their tumours when subsequently treated with platinum-based chemotherapy, a frequently-used treatment in ovarian cancer. The results show that a significant proportion of women with ovarian cancer could live longer if they received both treatments.
PARP inhibitors have the advantage of causing fewer and less toxic side-effects than traditional chemotherapy. They are being developed in clinical trials worldwide as a potential 'personalised' treatment for women with BRCA gene mutations, although some have also shown some benefit in patients with non-BRCA tumours.
The researchers also used high-tech new sequencing techniques to probe the precise genetic mechanisms responsible for drug resistance in ovarian tumours. Previously, tumours were thought to evolve resistance to both PARP inhibitors and platinum chemotherapy by acquiring new, secondary mutations to BRCA genes – transforming BRCA proteins from mutated, non-functioning forms back into working proteins.
However, in a small subset of six cases, the study found no sign of secondary BRCA mutations, suggesting that at least in these cases, cancer was developing resistance to PARP inhibitors and platinum-based chemotherapy in different ways.
Study leader Professor Stan Kaye, Cancer Research UK Professor of Medical Oncology at The Institute of Cancer Research, and Consultant at the Royal Marsden, said:
"Our study finds that for many women with ovarian cancer, it is not a case of either/or chemotherapy or PARP inhibitors – there is a good chance that they may respond to both. Although some scientists were concerned that using PARP inhibitors would prevent chemotherapy from being effective, we've resolved that concern by showing that both drug types can work in the same patients.
"Ovarian cancer is a difficult disease to treat and our research does underline the complexity of cancer, and the many different routes it can use to become resistant to treatment. But it also presents us with an opportunity, by showing us that two different types of drug treatment given in sequence could potentially extend lives."
###
Notes to editors
1. Although BRCA mutations are rare, affecting around one in every 500 women (in the USA), they dramatically increase the risk of developing cancers including breast and ovarian cancer and account for around 15 per cent of ovarian cancer cases. Source: National Cancer Institute factsheet BRCA1 and BRCA2: Cancer Risk and Genetic Testing: accessed online 30 August 2013.
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden Hospital and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk
The Royal Marsden NHS Foundation Trust
The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education.
Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 44,000 patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.
Since 2004, the hospital's charity, The Royal Marsden Cancer Charity, has helped raise over £100 million to build theatres, diagnostic centres, and drug development units.
Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.
For more information, visit http://www.royalmarsden.nhs.uk
About Cancer Research UK
Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research
The charity's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1861 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook
About The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
http://www.wellcome.ac.uk
Targeted treatment plus chemotherapy could benefit women with ovarian cancer
2013-10-11
ELSE PRESS RELEASES FROM THIS DATE:
Packaging stem cells in capsules for heart therapy
2013-10-11
Stem cell therapy for heart disease is happening. Around the world, thousands of heart disease patients have been treated in clinical studies with some form of bone marrow cells or stem cells.
But in many of those studies, the actual impact on heart function was modest or inconsistent. One reason is that most of the cells either don't stay in the heart or die soon after being introduced into the body.
Cardiology researchers at Emory have a solution for this problem. The researchers package stem cells in a capsule made of alginate, a gel-like substance. Once packaged, ...
Oral nutritional supplement use in pediatric inpatients decrease hospital stay and costs
2013-10-11
A new study has found that the use of oral nutritional supplements provided to pediatric patients during hospitalization was associated with a decrease in length of stay of 14.8 percent and a decrease in hospital stay costs of $1,768 per patient. The study, conducted by leading researchers at the University of Southern California, The Children's Hospital of Philadelphia, Harvard Medical School, Massachusetts General Hospital, and Precision Health Economics, and supported by Abbott, is being presented this weekend at the 2013 North American Society for Pediatric Gastroenterology, ...
New approach urged for 'abysmal' K-12 writing instruction
2013-10-11
EAST LANSING, Mich. — Writing instruction in U.S. classrooms is "abysmal" and the Common Core State Standards don't go far enough to address glaring gaps for students and teachers, a Michigan State University education scholar argues.
In a new study, Gary Troia calls for a fresh approach to professional development for teachers who must help students meet the new writing standards. His research, funded by the U.S. Department of Education's Institute of Education Sciences, appears in the journal School Psychology Review.
"We need to re-orient the way we think about teacher ...
Prostate cancer: A change in circulating tumor cells detection has high potential in the prediction
2013-10-11
Arnhem, 11 October 2013- A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.
"The research of the circulating tumour cells (CTC) is of utmost importance, because nowadays there is no reliable marker of both cancer-specific or overall survival in castration-resistant prostate cancer ...
Innovation in renewable-energy technologies is booming
2013-10-11
CAMBRIDGE, MA -- The number of patents issued for renewable-energy technologies has risen sharply over the last decade, according to new research from MIT and the Santa Fe Institute (SFI). The study shows that investments in research and development, as well as in the growth of markets for these products, have helped to spur this dramatic growth in innovation.
"We were quite surprised," says Jessika Trancik, an assistant professor of engineering systems at MIT and a co-author of the new report, published in the journal PLoS ONE. Trancik -- working with Luís Bettencourt ...
Predators vs. alien: European shrimps win predatory battles with an American invader
2013-10-11
A shrimp from America has been invading Europe's rivers and lakes for several decades, but something seems to be preventing this colonist from becoming numerous and problematic, like so many other invaders - such as the Californian grey squirrel and American crayfish. Could the resident European shrimps have something to do with this?
Jaimie Dick and his colleagues mapped the occurrence of the interloper and found it only existed where native shrimps were absent or rare. When native shrimps were common, the American shrimp simply could not establish and it disappeared. ...
Fish genital shape linked to predation
2013-10-11
When predators lurk nearby, male Bahamas mosquitofish (Gambusia hubbsi) change mating strategies, rejecting elaborate courting rituals for more frequent and sometimes forceful encounters with females.
But as a recent North Carolina State University study shows, mating strategies aren't the only things changing for G. hubbsi when predators abound. The shape and size of the male fish's genitalia are also linked to the presence or absence of predators.
NC State Ph.D. student Justa Heinen-Kay and assistant professor of biological sciences R. Brian Langerhans show, in ...
Compound in grapes, red wine could help treat multiple types of cancer, study finds
2013-10-11
VIDEO:
A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation...
Click here for more information.
COLUMBIA, Mo. — A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment. This research, which studied melanoma cells, ...
New technology can prevent cellular overload, dropped calls
2013-10-11
When a natural disaster strikes and too many people take to their mobile phones at once, cellular networks easily overload. But a University of British Columbia graduate student has developed a solution to ensure that calls don't get dropped and texts make it to their destination.
In a study published in the journal IEEE Transactions on Wireless Communications, Mai Hassan, a PhD student in the Department of Electrical and Computer Engineering, found a way to opportunistically use television and radio channels to transmit cellular signals when systems are pushed beyond ...
UC Irvine scientists help identify possible botulism blocker
2013-10-11
Irvine, Calif., Oct. 11, 2013 — U.S. and German scientists have decoded a key molecular gateway for the toxin that causes botulism, pointing the way to treatments that can keep the food-borne poison out of the bloodstream.
Study leaders Rongsheng Jin, associate professor of physiology & biophysics at UC Irvine, and Andreas Rummel of the Institute for Toxicology at Germany's Hannover Medical School created a three-dimensional crystal model of a complex protein compound in the botulinum neurotoxin. This compound binds to the inner lining of the small intestine and allows ...